Kraj: Australia
Język: angielski
Źródło: Department of Health (Therapeutic Goods Administration)
Rubella virus; Measles virus; Mumps virus
GlaxoSmithKline Australia Pty Ltd
Medicine Registered
1 PRIORIX _Measles-Mumps-Rubella vaccine live _ CONSUMER MEDICINE INFORMATION LEAFLET WHAT IS IN THIS LEAFLET This leaflet answers some of the common questions about PRIORIX vaccine. It does not contain all the available information. It does not take the place of talking to your doctor, nurse or pharmacist. All medicines and vaccines have risks and benefits. Your doctor has weighed the possible risks of you or your child having PRIORIX against the expected benefits. IF YOU HAVE ANY CONCERNS ABOUT PRIORIX TALK TO YOUR DOCTOR, NURSE OR PHARMACIST. KEEP THIS LEAFLET WITH THIS VACCINE. You may need to read it again. WHAT PRIORIX IS USED FOR PRIORIX is a vaccine used to prevent three diseases, measles, mumps and rubella (German measles). The vaccine is sometimes called MMR vaccine. Measles, mumps and rubella are all infectious diseases caused by viruses. The vaccine works by causing the body to produce its own protection (antibodies) against these diseases. MEASLES Measles is a highly infectious viral illness. Measles is spread by small droplets from the nose, throat or mouth of an infected person (often before it is obvious they have measles). Measles often begins with a fever, runny nose, hacking cough and conjunctivitis (eye inflammation). The rash appears 3-5 days after the onset of symptoms and spreads rapidly all over the body. Measles is often a severe disease complicated by ear infection and pneumonia (lung infection). Encephalitis (swelling of the brain) can also occur and can sometimes result in permanent brain damage or death. Unimmunised children in the following groups are at particular risk from severe measles infection: children with chronic c Przeczytaj cały dokument
1 PRIORIX® PRODUCT INFORMATION Measles, mumps and rubella vaccine live DESCRIPTION PRIORIX is a live virus vaccine for immunisation against measles, mumps and rubella. PRIORIX is a sterile lyophilised mixed preparation containing the attenuated Schwarz measles virus strain, the RIT 4385 strain of mumps virus (derived from the Jeryl Lynn strain) and the Wistar RA 27/3 rubella virus strain. Each virus strain is separately obtained by propagation in either chick embryo tissue cultures (mumps and measles) or MRC5 human diploid cells (rubella). PRIORIX is presented as a white to slightly pink pellet for reconstitution with sterile Water for Injection diluent. Each 0.5 mL dose of the reconstituted vaccine contains not less than 10 3.0 CCID 50 (cell culture infectious dose 50%) of the Schwarz measles, not less than 10 3.7 CCID 50 of the RIT 4385 mumps and not less than 10 3.0 CCID 50 of the Wistar RA 27/3 rubella virus strains. The three virus strains are mixed prior to lyophilisation. The lyophilised vaccine also contains lactose, neomycin sulphate, amino acids and sorbitol and mannitol as stabilisers. The manufacture of this product includes exposure to bovine derived materials. No evidence exists that any case of vCJD (considered to be the human form of bovine spongiform encephalopathy) has resulted from the administration of any vaccine product. PRIORIX meets the World Health Organisation requirements for manufacture of biological substances and for measles, mumps and rubella vaccines and combined vaccines (live). CLINICAL PHARMACOLOGY PRIORIX induces antibodie Przeczytaj cały dokument